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Abstract 
Objective: The purpose of the current study was to rigorously test Illness Management 
and Recovery (IMR) against an active control group in a sample that included Veterans.  
Methods: Participants with schizophrenia-spectrum disorders (N = 118) were randomly 
assigned to an IMR group or a weekly problem solving group intervention.  Blinded 
assessments were conducted at baseline, 9 months, and 18 months on measures of 
symptoms, functioning, illness self-management, medication adherence, subjective 
recovery experiences, and service utilization. Results: Study participants improved 
significantly over time in symptom severity, illness management, and quality of life, and 
had reduced emergency room visits, but there were no differences between IMR and 
support groups.  However, participation rates in both interventions were low. 
Conclusions:  This is the first negative trial of IMR.  Given the inclusion of an active 
control group and the low participation rates, further research is needed to understand 
factors affecting IMR effectiveness. Increased attention may need to be paid to facilitate 
more active participation in IMR, such as individual follow-up with consumers and the 
integration of IMR with ongoing treatment. 
  
The Illness Management and Recovery (IMR) program is a curriculum-based 
approach to helping consumers with severe mental illness set and achieve personal 
recovery goals and acquire the knowledge and skills to better manage illnesses (1). IMR 
has been tested in multiple quasi-experimental studies (2-7) and three randomized 
controlled trials (8-10).  A growing body of research has also addressed implementation 
and adaptations of IMR (11), illustrating its widespread popularity.  
IMR was explicitly developed to incorporate effective strategies for managing 
illnesses like schizophrenia (12), including psychoeducation, cognitive-behavioral 
approaches to medication adherence, relapse prevention, social skills training, and 
coping skills training.  The information and skills taught in IMR are conceptually 
organized around the stress-vulnerability model (13, 14), and are aimed at improving 
illness through reducing biological vulnerability (e.g., increasing medication adherence, 
reducing substance abuse), reducing the impact of stress (e.g., coping skills training, 
facilitating meaningful activities), and increasing social support (e.g., improving 
relationships).  The IMR curriculum includes 10 topic modules taught individually or in 
groups.  By learning to effectively manage mental illness and work towards personal 
goals, IMR seeks to help consumers become more active in treatment, to make progress 
in recovery, including both subjective (e.g., hopefulness) and objective aspects of 
recovery (e.g., improved role functioning), and to reduce use of inpatient and crisis 
services. 
Research on IMR as a package has demonstrated the program’s effectiveness, 
particularly regarding increased illness management and symptom reduction (11).  The 
randomized trials have been conducted in very different settings: thirteen community 
agencies in Israel (8), three supportive housing settings in New York City (9), and six 
Swedish psychosocial rehabilitation centers (10).  Each of these studies used a 
“treatment as usual” condition that varied substantially; however, common elements 
included case management, medication management, and access to other rehabilitation 
services.  Though not consistent across outcome domains, these trials all produced 
positive results showing advantages for IMR participants. However, no studies have 
compared IMR to equally intensive interventions to control for non-specific treatment 
factors, such a clinician attention.  More rigorous evaluation of the benefits of the 
curriculum and teaching methods above and beyond non-specific therapeutic factors is 
needed.   
In addition, none of the prior published work on IMR has addressed the needs of 
Veterans. The Department of Veterans Affairs (VA) is investing resources to improve 
mental health treatment for Veterans, including evidence-based community mental 
health programming (15) and an increased emphasis on recovery-oriented care (16).  
Despite these initiatives, Veterans’ needs are still great. For example, in 2004, the 
average length of inpatient psychiatric hospitalization was 13 days; however, rates of 
readmission were high, with 31% readmitted within 6 months (17).  One study directly 
comparing Veteran with non-Veteran consumers with schizophrenia found similar levels 
of subjective recovery (e.g., hope, satisfaction with life, and empowerment), but lower 
perceived knowledge about illness management among Veterans (18).  Taken together, 
these findings suggest the need for interventions that can help Veterans take greater 
control of their illness and rely less on costly mental health services. 
The purpose of the current study was to rigorously test IMR in a sample of 
Veterans and non-Veterans with schizophrenia-spectrum disorders to determine if IMR 
improves outcomes above the effects of an active control group.  We hypothesized that 
IMR would lead to greater improvements in symptoms, functioning, illness management, 
medication adherence, subjective experiences of recovery, and reduced utilization of 
crisis and hospital services. 
Methods 
 A randomized controlled trial compared group-based IMR to an equally intensive 
problem solving (PS) control group offered weekly for 9 months. All participants 
continued to receive other usual treatment, which could include medication 
management, case management, individual or group therapy, and other psychosocial 
treatment.  The study took place at a VA Medical Center Psychosocial Rehabilitation and 
Recovery Center and at a community mental health center (CMHC) in the same city.  
Recruitment occurred between September 2008 and October 2010, with assessments 
conducted at baseline, 9 months, and 18 months.  Procedures were approved by the 
Institutional Review Board at [xxx] university and the Research and Development 
committee of the [xxx] VA Medical Center. 
Participants 
 Inclusion criteria were: currently receiving (or newly admitted to) mental health 
services at the VA or CMHC; age 18 or older; diagnosis of schizophrenia or 
schizoaffective disorder; and willingness and ability to give informed consent. Exclusion 
criteria were: medical condition limiting participation in an 18-month study (e.g., end 
stage renal disease), or evidence of severe cognitive impairment based on a screener 
(19). All participants of the VA were Veterans (N=52) and 4 of the 66 CMHC participants 
were Veterans. 
 Participants were recruited through clinician referrals, self-referral, and a registry 
of individuals who had participated in previous research. Members of the research team 
attended clinical team meetings to describe the study and distribute brochures, which 
were then given to consumers and posted in treatment areas.  As shown in the study 
flow chart (See Figure 1 in supplemental materials), 118 participants were recruited and 
randomly assigned to either IMR (N = 60) or PS (N = 58).   
Program models 
Illness Management and Recovery was offered in small groups (less than 8), co-
facilitated by either an experienced masters level clinician or a doctoral level 
psychologist and by a doctoral student in clinical psychology. The initial facilitator was 
trained directly by Susan Gingerich and participated in biweekly phone supervision for 
several months.  Through the rest of the study, facilitators met regularly for peer 
supervision.  Facilitators used the IMR curriculum (20), incorporating psychoeducation, 
cognitive-behavioral approaches, relapse prevention, social skills training, and coping 
skills training.  Facilitators worked with group members to set personal recovery goals 
and address progress towards those goals throughout the intervention.  Home 
assignments helped participants apply newly learned skills and/or make progress on 
goals. Groups were open to rolling admission across the study period.  
Problem Solving was used to control for attention and time in groups. 
Participants were encouraged to discuss current concerns and receive group support for 
solving problems, but we did not use structured problem solving tasks. These groups 
were led by the same facilitators described above, who helped establish group 
expectations (attendance, confidentiality), encouraged participation, and provided 
process-oriented observations; there was no formal curriculum, goal setting, or 
homework assignments.  
Fidelity assessment.  To ensure that the experimental condition was following the 
IMR model and that the control condition was not, we audiotaped all sessions and rated 
fidelity using the IMR Treatment Integrity Scale (IT-IS) (21), a 16-item, behaviorally 
anchored scale. We randomly selected 60 IMR and 20 control sessions to rate.  Raters 
were four graduate students with experience providing IMR and trained to make fidelity 
ratings, and were not told which condition they were rating.  On a 5-point scale, mean 
total scale scores were significantly higher for IMR sessions (3.4±.8) than for PS 
sessions (2.2±.3), t = 11.68, p < .001. Means for each of the items were higher for IMR 
than PS, except “enlisting mutual support” which was similar across conditions.  
Measures 
Participants were interviewed at baseline, 9 months, and 18 months by trained 
raters blinded to study condition.  Participants were paid $20 for each interview.  We 
obtained data on emergency room and hospital utilization through medical records.  At 
baseline, diagnoses were assessed with the psychosis modules of the Structured 
Clinical Interview for DSM-IV (SCID) (22) administered by either a clinical psychologist 
or trained doctoral student.  Because IMR was designed to help consumers become 
more active in their own treatment and to make progress in recovery, we included a 
range of measures to tap activation and both subjective and objective indices of 
recovery.  
Psychiatric symptomatology was assessed by the Positive and Negative 
Syndrome Scale (PANSS; (23)), a widely-used, 30-item interview-based rating scale. 
The PANSS has demonstrated satisfactory internal consistency, test-retest reliability, 
and validity (23).  Raters were trained to an inter-rater reliability of .80 prior to 
interviewing participants. We examined the total score and five factors comprised of 
Positive symptoms, Negative symptoms, Emotional discomfort, Hostility or poor impulse 
control, and Cognitive symptoms (24).   
Quality of life was assessed with an abbreviated version of the Quality of Life 
Scale (25), commonly used in schizophrenia. The QLS includes questions and objective 
indicators for interviewers to rate social and occupational functioning during the prior 4 
weeks. The abbreviated version includes 7 of the original 21 items, providing a reliable, 
brief measure (26). 
Illness self-management was assessed with the consumer-rated Illness 
Management and Recovery Scale (27). Items are rated on a 5-point behaviorally 
anchored scale, and the mean across all 15 items forms an overall score, with higher 
scores indicating better self-management. The IMR Scales have shown internal 
consistency, stability, sensitivity to change over time, and correlations with indices of 
functioning, symptoms, and recovery (28-30).  
Patient activation was assessed with the short form, mental health version of the 
Patient Activation Measure (31).  Scores have a possible range of 0 (least activation) to 
100 (highest activation). The 13-item mental health version has been shown to have 
strong reliability in Rasch analyses, test-retest reliability, and correlates with related 
constructs (32), and has been used in other samples with schizophrenia (33-35). 
Medication adherence was assessed with the Morisky Scale, a 4-item scale with 
adequate reliability and validity across populations (36), including severe mental illness 
(37).  Participants answered “yes” or “no” to items related to medication adherence; a 
score sums the number of “yes” responses, with a lower score indicating better 
adherence.  
  Perceived recovery was assessed using the total score of the Recovery 
Assessment Scale (38). Respondents endorse 41 items (e.g., "I have a desire to 
succeed.") on a scale from 1 ("strongly disagree") to 5 ("strongly agree"). RAS total 
score has shown good test-retest reliability, internal consistency, and correlates with 
measures of self-esteem, empowerment, and quality of life (38).  
Hope was assessed using the 6-item Adult State Hope Scale (39), which has 
high internal consistency and convergent and discriminant validity (39). The scale has 
also been used in individuals with schizophrenia (40, 41).   
Service utilization was extracted from medical records, including number of visits 
to the emergency room and number of admissions and length of stay in inpatient units of 
the respective settings.  Data were extracted for 9 months prior to baseline, baseline to 9 
months, and 9 to 18 months.  
Data analysis 
We compared IMR and PS on background and outcome variables using X2 for 
categorical variables and t-tests for continuous variables. Intent-to-treat analyses 
compared changes in IMR and PS groups over time on the outcome measures.  To 
explore whether outcomes differed among consumers who had some engagement in 
their assigned intervention, we also conducted analyses comparing those randomized 
who attended at least one group. These analyses produced similar results as the intent-
to-treat analyses, and are not presented.   
We followed a similar analysis approach of recent RCTs using mixed effects 
regression analyses of mean response profiles (42, 43).  We included the baseline 
measure for a given outcome variable as a covariate, as well as site, and fit adjusted 
mean response profile models (44) using SAS PROC MIXED for continuous outcomes 
(interview data) and SAS PROC GENMOD (Poisson regression) for count outcomes 
(service data).  This approach can accommodate correlated residuals by selecting 
appropriate covariance structures as well as missing data with maximum likelihood 
estimation (45).  The group main effects in this model (i.e., the difference in group mean 
response profiles between the IMR and problem solving interventions at post-treatment 
and follow-up) were the primary test of the study hypotheses. To evaluate changes over 
time across the outcome measures from baseline to 9 and 18 months, we performed 
similar analyses, but included all measurement occasions as dependent variables using 
SAS PROC MIXED and SAS PROC GENMOD. Finally, we examined if rates of 
intervention exposure (% of attendance for the intervention) were related to changes in 
outcomes over time. We employed the significance level at a p value of .05 or less. 
Results 
Participants assigned to IMR did not differ significantly from those assigned to PS 
on baseline measures (See Table 1). Participants were predominantly male (80%), 
African American (61%), and living independently (70%).  The mean age was 47.7±8.9.  
Most were unemployed (86%) and reported an annual income of less than $10,000 
(63%).   
Rates of treatment participation were low for both groups, but did not significantly 
differ. For IMR, 14 (23%) attended no sessions, 29 (48%) attended fewer than half the 
scheduled sessions, and 17 (28%) attended half or more.  For PS, 20 (34%) attended no 
sessions, 28 (48%) attended fewer than half the scheduled sessions, and 10 (17%) 
attended half or more. Older age, lower hostility, fewer psychotic symptoms, and more 
education were associated with higher attendance in both conditions (see (AuthorCite) 
for more details). 
Outcomes across time are shown in Table 2. The mean response profile 
analyses revealed no group differences between IMR and PS on any of the outcomes. 
Time effects showed improvements in several variables, including all symptom domains 
(Cohen’s d >.5), functioning on the Abbreviated Quality of Life Scale (Cohen’s d =.4), 
self-reported illness management (Cohen’s d = .4), and emergency room visits (Cohen’s 
d = .3). There were main site effects with consumers from the VA having lower scores on 
some of the outcome variables (i.e., self-reported illness management [p<.05], total RAS 
scores [p<.05]), but there were no site by group interactions.  Additional analyses 
accounting for percent of sessions attended indicated that treatment exposure did not 
explain the variance in outcomes.  
Discussion 
Participants in both groups improved significantly in a number of domains related 
to illness management, including symptoms, psychosocial functioning, self-rated illness 
management, and emergency room use.  However, in contrast to three other 
randomized trials showing some advantages for IMR (8-10) over usual care, there were 
no significant differences between IMR and the problem-solving group on any outcomes.  
We speculate on several possible reasons for these findings. 
This was the first randomized trial of IMR that controlled for non-specific 
treatment factors with an active, equally intensive intervention, rather than usual 
services.  While the control intervention did not take a structured approach to teaching 
problem solving, it did provide a forum to discuss problems and concerns with 
experienced clinicians and to receive support from group members, which have been 
identified as effective components of group interventions (47, 48).  Our fidelity ratings 
showed no differences between the IMR and problem solving groups in enlisting mutual 
support. Thus, it is possible that the benefits of IMR over usual services shown in 
previous studies are primarily due to non-specific therapeutic factors in IMR groups, 
rather than the specific curriculum, teaching methods, and recovery orientation of IMR.  
A recent Cochrane review of cognitive behavioral therapies for schizophrenia showed 
similar lack of findings when compared to active controls (49). However, there are 
important alternative explanations to consider related to implementation and participation 
of the group interventions.  
Participation rates in both the IMR and problem solving groups were lower than 
desired, which could have limited the effect of intervention. Only 28% of consumers 
assigned to IMR, and 17% of those assigned to problem solving, participated in more 
than half of the scheduled groups, and 23% and 34% assigned to each respective group 
attended no sessions. Although percentage of sessions attended did not account for 
outcomes in our analyses for either group, it is conceivable that a minimum threshold of 
exposure to IMR is necessary to detect treatment benefits, and potentially even higher 
levels of exposure are necessary to distinguish specific from non-specific effects of IMR. 
Our rates of exposure to IMR are lower than those reported in the previous three 
controlled trials of IMR. One study in a residential setting (9) reported that 54% of 
consumers (almost twice our rate) attended at least half of the sessions. Participants in 
Färdig’s (10) sample attended an average of 30 out of 40 sessions, and all attended at 
least half; however, participants were recruited based on consistent attendance in prior 
mental health services and implementation of IMR focused heavily on consumer 
engagement (Färdig, personal communication, 12/19/12). The controlled trial that took 
place in Israel reported 7% were dropped from analyses for not participating, but 
completion rates for IMR were not reported.   
In our study, participants were asked to attend weekly for 9 months. Although 
group leaders attempted to facilitate attendance with reminders and phone calls, 
assertive outreach was not feasible.  This may represent a common scenario in 
community mental health and suggests that additional engagement strategies may be 
needed to engage participants in a weekly intervention for the better part of a year. A 
possible limitation in our study design was rolling admission into groups.  This was done 
so that participants would not wait long between recruitment and intervention; however, 
rolling admission may have led to less group cohesion or mutual accountability, which 
could have impacted participation. In addition, in both settings there was a lack of 
integration of IMR with other services and with documentation in medical records.  The 
lack of integration may have limited the ability of other treatment providers to facilitate 
consumers’ work on recovery goals, encourage IMR attendance, and reinforce skills 
learned in the program.   
In addition to the integration with other treatment, the interaction of IMR with 
other services is poorly understood and may have affected responsiveness in the current 
trial. Veterans participating in the current trial generally had received extensive services 
prior to participating in IMR, including psychoeducation, coping skills, and relapse 
prevention groups. It is unclear from previous IMR trials how many participants accessed 
other rehabilitation services concurrently or previously. Although we did control for site in 
the analyses, more work is needed in the VA context, particularly as illness management 
is a required component of recovery-oriented care in VA psychosocial and recovery 
centers (50). Finally, our available sample sizes were somewhat smaller than our a priori 
power calculation (n=62 for each group assuming 20% attrition), while attrition was 
higher resulting in slightly less overall power to detect moderate effects. 
Conclusions 
This study highlights important areas for future study of IMR effectiveness.  
Although IMR did not have an advantage, participants across groups experienced 
improvements in several domains.  Issues of treatment exposure, potency, context, and 
population served may have all impacted outcomes and serve as important targets for 
future study.  
Table 1: Descriptive statistics of participant background characteristics. 
 IMR (N=60) PS (N=58) Total (N=118) 
Variable N % N % N % 
Site:        
  VA 25 42 27 47 52 44 
  CMHC 35 58 31 53 66 56 
Gender:       
  Male 46 77 48 83 94 80 
  Female 14 23 10 17 24 20 
Ethnicity:        
  African American 32 53 40 69 72 61 
  White 22 37 18 31 40 34 
  More than one race 6 10 0 0 6 5 
Diagnosis:        
  Schizophrenia 27 45 27 47 54 46 
  Schizoaffective  33 55 31 53 64 54 
Marital Status:       
  Not Married 52 87 47 81 99 84 
  Married/ Living with partner 6 10 10 17 16 14 
  Missing 2 3 1 2 3 3 
Housing:       
  Non-independent 17 28 14 24 31 26 
  Independent 40 80 42 72 82 70 
  Homeless 2 3 0 0 2 2 
  Missing 1 2 2 3 3 3 
Educational Attainment: 
  Less than high school 20 33 20 35 40 34 
  High school/GED 20 33 19 33 39 33 
  College and above 19 32 18 31 36 31 
  Missing 1 2 1 2 2 2 
Employment Status:       
  Employed 9 15 6 10 9 13 
  Unemployed 50 83 51 88 101 86 
  Missing 1 2 1 2 2 2 
Annual Income Level: 
  $0 to < $10,000 44 73 30 52 74 63 
  $10,000 to < $20,000 10 17 15 26 25 21 
  $20,000 to < $30,000 0 0 3 5 3 3 
  $30,000 or higher 3 5. 5 9 8 7 
  Missing 3 5. 5 9 8 7 
Table 2. Descriptive Statistics, Group Effects, and Time Effects 
                          
  IMR PS             
  Baseline (N=59) 
9 MO. 
(N=44) 
18 MO. 
(N=37) 
Baseline 
(N=57) 
9 MO. 
(N=40) 
18 MO. 
(N=33) Group Effect Time Effect 
 M SD M SD M SD M SD M SD M SD df F sig df F sig. 
Interview-based measures                                     
PANSS TOTAL 75.1 16.1 68.5 18.5 61.9 17.1 76.1 15.3 66.6 14.9 65.3 19.6 1, 82.7 .95 n.s 2, 79.8 24.29 p<.001 
   Positive Symptoms 16.3 5.3 14.1 6.2 13.5 5.2 15.2 4.5 12.6 4.9 13.0 5.3 1, 81.8 .59 n.s 2, 78.9 15.93 p<.001 
   Negative Symptoms 18.7 5.8 18.5 5.8 16.7 6.8 19.5 5.3 17.9 6.2 18.5 6.7 1, 80.2 .31 n.s 2, 80.6 3.16 p<.05 
   Emotional Discomfort 12.4 4.6 10.8 5.1 10.6 4.7 12.8 4.6 10.6 4.1 10.7 4.4 1, 82.7 .24 n.s 2, 80.0 8.75 p<.001 
   Hostility 8.4 3.2 7.3 2.9 4.9 1.7 8.9 3.2 7.8 2.4 5.8 2.4 1, 74.8 1.04 n.s 2, 85.8 40.70 p<.001 
   Cognitive Symptoms 17.1 5.3 15.7 6.0 14.1 5.5 17.2 5.8 15.6 5.7 15.5 6.6 1, 84.6 1.10 n.s 2, 79.7 14.23 p<.001 
QLS 3.1 1.1 3.3 1.1 3.5 1.0 2.8 1.0 3.3 1.1 3.3 1.3 1, 76.1 .08 n.s 2, 81.6 7.06 p<.01 
Illness Management and 
Recovery 3.5 .5 3.5 .6 3.6 .5 3.3 .5 3.6 .6 3.5 .6 1, 77.6 .02 n.s 2, 80.4 3.55 p<.05 
Patient Activation 53.2 15.3 55.1 15.1 56.7 15.5 55.2 17.4 57.9 18.1 58.2 17.3 1, 80.3 .22 n.s 2, 82.9 1.11 n.s 
Medication Adherence 1.4 1.3 1.3 1.3 1.1 1.3 1.7 1.2 1.2 1.1 1.3 1.1 1, 82.4 .11 n.s 2, 82.1 3.01 n.s 
RAS TOTAL 3.1 .4 3.1 .4 3.1 .4 3.0 .4 3.1 .4 3.1 .5 1, 76.5 .50 n.s 2, 77.0 2.53 n.s 
Hope 3.0 .6 3.0 .6 2.9 .6 2.9 .7 3.0 .7 3.0 .7 1, 83.8 .38 n.s 2, 84.1 .50 n.s 
Service utilization                         df x2 sig. df x2 sig. 
ER visit 2.3 4.1 1.9 3.6 1.3 2.6 2.4 3.6 1.3 1.9 1.3 2.5 1 1.06 n.s 1 5.87 p<.05 
Psych ER visit .4 1.1 .3 .9 .2 .6 .5 1.2 .2 .6 .3 1.0 1 1.16 n.s 1 2.35 n.s 
Inpatient admissions .4 .8 .4 .8 .4 .7 .7 1.1 .4 .7 .3 .6 1 .70 n.s 1 .71 n.s 
Inpatient psych admissions .3 .6 .3 .5 .3 .7 .4 .8 .2 .5 .2 .6 1 .72 n.s 1 .75 n.s 
Length of stay in hospital 6.9 17.1 3.7 16.5 6.1 15.1 7.8 15.0 3.3 17.2 5.5 15.6 1 .84 n.s 1 .69 n.s 
Length of stay in psych 
hospital 6.2 16.9 4.5 10.8 5.7 15.1 5.7 14.0 4.4 11.6 4.7 15.6 1 .74 n.s 1 .72 n.s 
Note: Descriptive statistics are simple statistics for means without any covariates adjusted, but group and time effects were tested for the mean differences adjusting for the 
covariates (i.e., baseline scores and site) and accounting for the missing data. 
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